There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Lion Biotechnologies Inc (NASDAQ: LBIO) and Alkermes (NASDAQ: ALKS) with bullish sentiments.
Lion Biotechnologies Inc (NASDAQ: LBIO)
In a report released today, Mark Breidenbach from Roth Capital initiated coverage with a Buy rating on Lion Biotechnologies Inc (NASDAQ: LBIO) and a price target of $14. The company’s shares opened today at $7.25.
“We are re-establishing estimates, a Buy rating, and $14 price target for Lion Biotechnologies based on a risk adjusted earnings and revenues multiples valuation. We believe 2017 could be a transformational year for the company with early results expected from an ongoing Phase 2 trial of TIL therapy in melanoma, the first of its kind to use centralized manufacturing.”
According to TipRanks.com, Breidenbach is ranked 0 out of 5 stars with an average return of -20.2% and a 30.2% success rate. Breidenbach covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, RXi Pharmaceuticals Corp, and Mateon Therapeutics Inc.
Lion Biotechnologies Inc has an analyst consensus of Strong Buy.
Alkermes (NASDAQ: ALKS)
J.P. Morgan analyst Cory Kasimov reiterated a Buy rating on Alkermes (NASDAQ: ALKS) today and set a price target of $78. The company’s shares opened today at $58.17, close to its 52-week high of $60.74.
According to TipRanks.com, Kasimov is ranked 0 out of 5 stars with an average return of -7.8% and a 38.5% success rate. Kasimov covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals Inc, Global Blood Therapeutics, and Karyopharm Therapeutics.
Alkermes has an analyst consensus of Strong Buy, with a price target consensus of $71.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.